Akums Drugs and Pharmaceuticals DuPont analysis

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025


0.69×	0.67×	1.00×
1.04×	1.04×	1.11×
9.1%	8.4%	7.6%
0.91×	0.91×	1.00×
1.64×	1.64×	1.34×
9.7%	8.8%	11.2%
8.0%	8.0%	11.1%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

AKUMS₹741.05

Akums Drugs and Pharmaceuticals Ltd.

· Pharma & Health

₹ CrorePeersALIVUS AGARWALEYE ADVENZYMES APLLTD AARTIPHARM AARTIDRUGS CORONA HCGMcap ₹11,346 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×	1.00	0.67	0.69
Interest Burden (Pretax/EBIT) ×	1.11	1.04	1.04
EBIT Margin %	7.55	8.43	9.09
Asset Turnover ×	1.00	0.91	0.91
Financial Leverage (Assets/Equity) ×	1.34	1.64	1.64
ROE (5-step product, year-end total equity) %	11.21	8.75	9.67
ROE (owners' profit / average owners' equity) %	11.10	8.02	8.02

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.